Valuation: Indivior

Market Cap 4.94B 4.32B 3.98B 3.68B 6.98B 471B 7.1B 47.6B 18.69B 232B 18.54B 18.14B 798B P/E 2026 *
12.8x
P/E 2027 * 11.2x
Enterprise Value 4.99B 4.37B 4.03B 3.72B 7.06B 476B 7.18B 48.13B 18.9B 235B 18.74B 18.34B 806B EV / Sales 2026 *
3.97x
EV / Sales 2027 * 3.47x
Free-Float
97.22%
Yield 2026 *
-
Yield 2027 * -
Change 5-day change 1-year change 3-year change Capi.($)
+0.09%+1.57% - - 4.94B
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
+0.66%-1.42%-29.26%-39.30% 218B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
Average -0.80%-3.25%+24.40%+55.51% 397.1B
Weighted average by Cap. -0.56%-2.96%+35.28%+81.27%

Financials

2026 *2027 *
Net sales 1.26B 1.1B 1.01B 937M 1.78B 120B 1.81B 12.13B 4.76B 59.1B 4.72B 4.62B 203B 1.31B 1.14B 1.06B 975M 1.85B 125B 1.88B 12.61B 4.95B 61.45B 4.91B 4.8B 211B
Net income 414M 363M 334M 309M 586M 39.53B 596M 4B 1.57B 19.47B 1.56B 1.52B 66.95B 473M 414M 382M 352M 669M 45.1B 680M 4.56B 1.79B 22.22B 1.78B 1.74B 76.38B
Net Debt 54.5M 47.67M 43.97M 40.61M 77.06M 5.2B 78.35M 525M 206M 2.56B 205M 200M 8.8B -403M -353M -325M -301M -570M -38.47B -580M -3.89B -1.53B -18.95B -1.51B -1.48B -65.16B
Logo Indivior
Indivior Pharmaceuticals, Inc. is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. It sells its products in the United States and in other selected areas of the world.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-